Inhibition of RANKL a key mediator of osteoclast formation – new opportunities in osteoporosis treatment
The perspective of clinical use fully human monoclonal antibody that inhibits bone resorption by neutralizing RANKL holds enormous promise for the treatment of large number of bone loss diseases. Denosumab is a novel antibody that binds to RANKL and inhibits bone resorption. Administered subcutaneo...
Αποθηκεύτηκε σε:
| Κύριοι συγγραφείς: | , , , , |
|---|---|
| Μορφή: | Artigo |
| Γλώσσα: | Inglês |
| Έκδοση: |
Medical University of Lublin
2025-04-01
|
| Σειρά: | Current Issues in Pharmacy and Medical Sciences |
| Θέματα: | |
| Διαθέσιμο Online: | https://czasopisma.umlub.pl/curipms/article/view/2993 |
| Ετικέτες: |
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!
|